The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer

被引:1
|
作者
Kang, Ho Won [1 ]
Jung, Hae Do [2 ]
Lee, Joo Yong [3 ]
Kwon, Jong Kyou [4 ]
Jeh, Seong Uk [5 ]
Cho, Kang Su [6 ]
Ham, Won Sik [3 ]
Choi, Young Deuk [3 ]
机构
[1] Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Dept Urol, Cheongju, South Korea
[2] Yonsei Univ, Coll Med, Yongin Severance Hosp, Dept Urol, Yongin, South Korea
[3] Yonsei Univ, Coll Med, Urol Sci Inst, Severance Hosp,Dept Urol, 50-1 Yonsei Ro, Seoul 03722, South Korea
[4] Yonsei Univ Hlth Syst, Severance Check Up, Dept Urol, Seoul, South Korea
[5] Gyeongsang Natl Univ, Sch Med, Dept Urol, Jinju, South Korea
[6] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Urol Sci Inst,Dept Urol, Seoul, South Korea
关键词
Prostate-specific Antigen; Prostate-specific Antigen Density; Prostatic Neoplasms; Prostatectomy; Biochemical Recurrence; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; DISEASE RECURRENCE; STRATIFICATION; MORTALITY; BRACHYTHERAPY; PREDICTION; SURVIVAL; TRENDS; DEATH;
D O I
10.3346/jkms.2018.33.e36
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Significant clinical heterogeneity within contemporary risk group is well known, particularly for those with intermediate-risk prostate cancer (IRPCa). Our study aimed to analyze the ability of the Cancer of the Prostate Risk Assessment (CAPRA) score to discern between favorable and non-favorable risk in patients with IRPCa. Methods: We retrospectively reviewed the data of 203 IRPCa patients who underwent extraperitoneal robot-assisted radical prostatectomy (RARP) performed by a single surgeon. Pathologic favorable IRPCa was defined as a Gleason score <= 6 and organ-confined stage at surgical pathology. The CAPRA score was compared with two established criteria for the within-group discrimination ability. Results: Overall, 38 patients (18.7% of the IRPCa cohort) had favorable pathologic features after RARP. The CAPRA score significantly correlated with established criteria I and II and was inversely associated with favorable pathology (all P < 0.001). The area under the receiver operating characteristic curve for the discriminative ability between favorable and non-favorable pathology was 0.679 for the CAPRA score and 0.610 and 0.661 for established criteria I and II, respectively. During a median 37.8 (interquartile range, 24.6-60.2) months of follow-up, 66 patients (32.5%) experienced biochemical recurrence (BCR). Cox regression analysis revealed that the CAPRA score, as a continuous sum score model or 3-group risk model, was an independent predictor of BCR after RARP. Conclusion: The within-group discrimination ability of preoperative CAPRA score might help in patient counseling and selecting optimal treatments for those with IRPCa.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Risk Group and Death From Prostate Cancer Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer
    Raldow, Ann C.
    Zhang, Danjie
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    JAMA ONCOLOGY, 2015, 1 (03) : 334 - 340
  • [2] Personalizing the Management of Men with Intermediate-risk Prostate Cancer
    D'Amico, Anthony V.
    EUROPEAN UROLOGY, 2013, 64 (06) : 903 - 904
  • [3] Re: Risk Group and Death from Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-Risk Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 196 (02): : 412 - 413
  • [4] Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer
    Gandaglia, Giorgio
    Briganti, Alberto
    Montorsi, Francesco
    EUROPEAN UROLOGY, 2016, 69 (02) : 370 - 370
  • [5] Outcomes for Men with Intermediate-risk Prostate Cancer on Active Surveillance
    Courtney, P. T.
    Deka, R.
    Cherry, D. R.
    Nelson, T. J.
    Luterstein, E.
    Salans, M. A.
    Yip, A. T. T.
    Nalawade, V.
    Parsons, J. K.
    Kader, K.
    Stewart, T. F.
    Rose, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S121 - S122
  • [6] Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Diven, Marshall A.
    Tshering, Lhaden
    Ma, Xiaoyue
    Hu, Jim C.
    Barbieri, Christopher
    McClure, Timothy
    Nagar, Himanshu
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [7] UTILITY OF ONCOTYPE DX IN MEN WITH INTERMEDIATE-RISK PROSTATE CANCER
    Cantu, Miguel
    Golan, Ron
    McCarthy, Hiral
    Scognamiglio, Theresa
    McClure, Timothy
    Barbieri, Christopher
    Robinson, Brian
    Khani, Francesca
    JOURNAL OF UROLOGY, 2018, 199 (04): : E207 - E207
  • [8] Insignificant disease among men with intermediate-risk prostate cancer
    Sung Kyu Hong
    Emily Vertosick
    Daniel D. Sjoberg
    Peter T. Scardino
    James A. Eastham
    World Journal of Urology, 2014, 32 : 1417 - 1421
  • [9] Insignificant disease among men with intermediate-risk prostate cancer
    Hong, Sung Kyu
    Vertosick, Emily
    Sjoberg, Daniel D.
    Scardino, Peter T.
    Eastham, James A.
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1417 - 1421
  • [10] Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Cooperberg, Matthew R.
    Cowan, Janet E.
    Hilton, Joan F.
    Reese, Adam C.
    Zaid, Harras B.
    Porten, Sima P.
    Shinohara, Katsuto
    Meng, Maxwell V.
    Greene, Kirsten L.
    Carroll, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 228 - 234